







an Open Access Journal by MDPI

New Insights into Esophageal Cancer Chemotherapy

Guest Editor:

Dr. Kenneth Meredith

Department of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA

Deadline for manuscript submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Recent advancements in esophageal cancer chemotherapy have provided valuable insights into more effective treatment strategies. Researchers have uncovered novel drug combinations that target specific molecular pathways involved in esophageal cancer progression. These approaches aim to enhance the efficacy of chemotherapy while minimizing adverse side effects. Additionally, personalized treatment plans based on a patient's genetic profile are becoming increasingly common, allowing for tailored therapies that improve overall outcomes. These innovative insights offer hope for more successful and less invasive management of esophageal cancer, potentially leading to improved patient survival rates and a better quality of life during treatment.

Dr. Kenneth Meredith *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us